19 May 2013
Keywords: nicox, provides, details, ph, iii, naproxcinod, trials
Article | 18 September 2006
French drugmaker NicOx SA has announced the details of its proposed Phase III trial program, designed to assess naproxcinod (HCT 3012) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
18 September 2006
17 May 2013
© 2013 thepharmaletter.com